Evolutionary therapy
Our current approach to cancer treatment has been largely driven by finding molecular targets, those patients fortunate enough to have a targetable mutation will receive a fixed treatment schedule designed to deliver the maximum tolerated dose (MTD). These therapies generally achieve impressive short-term responses, that unfortunately give way to treatment resistance and tumor relapse. The importance of evolution during both tumor progression, metastasis and treatment response is becoming more widely accepted. However, MTD treatment strategies continue to dominate the precision oncology landscape and ignore the fact that treatments drive the evolution of resistance. Here we present an integrated theoretical, experimental and clinical approach to develop treatment strategies that specifically embrace cancer evolution. We will consider the importance of using treatment response as a critical driver of subsequent treatment decisions, rather than fixed strategies that ignore it. Through the integrated application of drug treatments and drug holidays we will illustrate that, evolutionary therapy can drive either tumor control or extinction. Our results strongly indicate that the future of precision medicine shouldn’t be in the development of new drugs but rather in the smarter evolutionary application of preexisting ones.
Date: 5 February 2021, 14:00 (Friday, 3rd week, Hilary 2021)
Venue: Mathematical Institute, Woodstock Road OX2 6GG
Speaker: Professor Alexander Andersonon (Moffitt Cancer Centre)
Organising department: Mathematical Institute
Organiser: Sara Jolliffe (University of Oxford)
Organiser contact email address: sara.jolliffe@maths.ox.ac.uk
Host: Dr Ruth Baker (University of Oxford)
Part of: Mathematical Biology and Ecology
Booking required?: Not required
Audience: Members of the University only
Editor: Sara Jolliffe